Format

Send to

Choose Destination
Adv Ther. 2019 Sep 12. doi: 10.1007/s12325-019-01074-6. [Epub ahead of print]

Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study.

Author information

1
Centre for Heart, Lung and Vascular Health, University of British Columbia, 3333 University Way, Kelowna, BC, V1V 1V7, Canada. amdpatrician@gmail.com.
2
Department of Toxicology and Pharmacogenetics, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia.
3
Department of Integrative Physiology, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia.
4
Department of Health Studies, University of Split, Ruđera Boškovića 35, 21000, Split, Croatia.
5
Department of Pathology, Forensic Medicine and Citology, University Hospital Centre Split, Spinčićeva 1, 21000, Split, Croatia.
6
Centre for Heart, Lung and Vascular Health, University of British Columbia, 3333 University Way, Kelowna, BC, V1V 1V7, Canada.

Abstract

INTRODUCTION:

Therapeutic effects of cannabidiol (CBD) in specialized populations continue to emerge. Despite supra-physiological dosing being shown to be tolerable in various pathologies, optimization of CBD absorption has obvious benefits for general health and recreational usage. Our objectives were to: (1) to investigate a joint pharmacokinetic-physiological time course of multiple recreational-equivalent (< 100 mg) dosages of oral CBD in young healthy adults and (2) evaluate a newly developed technology (TurboCBD™) for the enhanced delivery of CBD.

METHODS:

In a double-blinded, placebo-controlled, cross-over design, 12 participants received placebo, generic 45 or 90 mg of CBD, or TurboCBD™ delivery technology capsules on five separate occasions.

RESULTS:

Although there were no differences in the 45 mg conditions, circulating CBD levels were higher with the TurboCBD™ 90 mg group at both 90 (+ 86%) and 120 (+ 65%) min compared with the 90 mg control (p < 0.05). Total area under the curve tended to be higher with TurboCBD™ 90 mg compared with 90 mg (10,865 ± 6322 ng ml-1 vs. 7114 ± 2978 ng ml-1; p = 0.088). Only the TurboCBD™ 90 mg dose was elevated greater than placebo at 30 min (p = 0.017) and remained elevated at 4 h (p = 0.002).

CONCLUSION:

Consistent with higher bioavailability, TurboCBD™ 90 mg at the peak CBD concentration was associated with an increase in cerebral perfusion and slight reduction in blood pressure compared with baseline and the 90 mg control. Further studies are needed to establish the mechanisms of action of this technology and to explore the therapeutic potential of acute and chronic dosing on more at-risk populations.

FUNDING:

Lexaria Bioscience Corp.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT03295903.

KEYWORDS:

Cannabidiol; Cerebrovascular conductance; Gas chromatography-mass spectrometry; Pharmacokinetics 

PMID:
31512143
DOI:
10.1007/s12325-019-01074-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center